 |
[Apha Biz=(Chicago) Reporter Paul Lee] The court ruled in favor of the Fair Trade Commission, which sanctioned Daewoong Pharmaceutical's unfair inducement of customers.
According to the Fair Trade Commission on the 12th, the Seoul High Court ruled that the Fair Trade Commission nearly won in a lawsuit for the cancellation of correction and penalty payment orders filed by Daewoong Pharmaceutical Co. and Daewoong on Aug. 30 this year.
The Fair Trade Commission fined Daewoong a total of 2.297 billion won (2.146 billion won for Daewoong Pharmaceutical and 151 million won for Daewoong) on March 11, 2021 for obstructing competitors' sale of cloned drugs by unfairly filing a lawsuit against patent infringement and linking them to their business activities.
Daewoong Pharmaceutical and Daewoong filed an administrative suit with the Seoul High Court on April 21, 2021, in defiance of the above disposition.
However, the Seoul High Court ruled that the FTC's disposition was legitimate. However, the court canceled some of the fines (11 million won) for Daewoong, pointing to errors in the FTC's calculation of fines.
Alphabiz Reporter Paul Lee(hoondork1977@alphabiz.co.kr)
